Last updated on July 2018

INOVATYON STUDY -International Randomized Study in Patients With Ovarian Cancer

Brief description of study

The objective of this multicentric, randomised, Phase III study is to demonstrate superiority, in terms of prolonged survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD) versus carboplatin and PLD.

Patients will be randomised to:

Arm A: PLD 30 mg/m2 and carboplatin AUC 5 Arm B: PLD 30 mg/m2 and trabectedin 1.1 mg/m2 Patients'/subjects' characteristics: patients over 18 years of age with advanced, progressive ovarian cancer 6-12 months after completion of first line treatment with platinum-based chemotherapy.

Clinical Study Identifier: NCT01379989

Contact Investigators or Research Sites near you

Start Over

Vincenzo Ferraù

Ospedale S. Vincenzo
Taormina, Italy